Literature DB >> 9024738

Putting low-density lipoproteins at center stage in atherogenesis.

A D Sniderman1, T Pedersen, J Kjekshus.   

Abstract

This article argues that major risk factors such as diabetes or hypertension increase the risk of vascular disease principally by amplifying the malign interactions of low-density lipoprotein (LDL) particles with the arterial wall and, consequently, that LDL is the first and foremost factor in the pathogenesis of vascular disease. We conclude that marked reduction of the LDL particle number should be the cornerstone of therapy in those with vascular disease or in those at high risk of vascular disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9024738     DOI: 10.1016/s0002-9149(96)00677-7

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

Review 1.  Plasma apolipoproteins and risk for age related maculopathy.

Authors:  N Dashti; G McGwin; C Owsley; C A Curcio
Journal:  Br J Ophthalmol       Date:  2006-05-24       Impact factor: 4.638

Review 2.  Diagnosis and treatment of apolipoprotein B dyslipoproteinemias.

Authors:  Allan Sniderman; Patrick Couture; Jacqueline de Graaf
Journal:  Nat Rev Endocrinol       Date:  2010-04-27       Impact factor: 43.330

3.  Ethnic differences in low-density lipoprotein particle size in hypertensive adults.

Authors:  Iftikhar J Kullo; M Fuad Jan; Kent R Bailey; Thomas H Mosley; Stephen T Turner
Journal:  J Clin Lipidol       Date:  2007-07       Impact factor: 4.766

4.  Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes.

Authors:  N Tolonen; C Forsblom; L Thorn; J Wadén; M Rosengård-Bärlund; M Saraheimo; M Feodoroff; V-P Mäkinen; D Gordin; M-R Taskinen; P-H Groop
Journal:  Diabetologia       Date:  2009-10-10       Impact factor: 10.122

5.  Do age and baseline LDL cholesterol levels determine the effect of regular exercise on plasma lipoprotein cholesterol and apolipoprotein B levels?

Authors:  Theodore J Angelopoulos; Stephen A Sivo; George A Kyriazis; Jonathan D Caplan; Robert F Zoeller; Joshua Lowndes; Richard L Seip; Paul D Thompson
Journal:  Eur J Appl Physiol       Date:  2007-08-14       Impact factor: 3.078

6.  Naringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in Ldlr⁻/⁻ mice.

Authors:  Julia M Assini; Erin E Mulvihill; Brian G Sutherland; Dawn E Telford; Cynthia G Sawyez; Sarah L Felder; Sanjiv Chhoker; Jane Y Edwards; Robert Gros; Murray W Huff
Journal:  J Lipid Res       Date:  2012-12-26       Impact factor: 5.922

7.  Comparison of assessment techniques: plasma lipid and lipoproteins related to the metabolic syndrome.

Authors:  Brenda M Davy; Kevin P Davy
Journal:  Lipids Health Dis       Date:  2006-01-31       Impact factor: 3.876

8.  The apolipoprotein B/apolipoprotein A-I ratio as a potential marker of plasma atherogenicity.

Authors:  Anastasiya M Kaneva; Natalya N Potolitsyna; Evgeny R Bojko; Jon Ø Odland
Journal:  Dis Markers       Date:  2015-03-23       Impact factor: 3.434

9.  Apolipoprotein B/A1 Ratio as a Diagnostic Alternative to Triglycerides and HDL-Cholesterol for the Prediction of Metabolic Syndrome among Hypertensives in Kazakhstan.

Authors:  Alma Nurtazina; Dana Kozhakhmetova; Daulet Dautov; Aizhan Shakhanova; Vijay Kumar Chattu
Journal:  Diagnostics (Basel)       Date:  2020-07-23

10.  Apolipoprotein B/apolipoprotein A1 ratio and mortality among incident peritoneal dialysis patients.

Authors:  Xiaojiang Zhan; Yanbing Chen; Caixia Yan; Siyi Liu; Lijuan Deng; Yuting Yang; Panlin Qiu; Dan Pan; Bingxiang Zeng; Qinkai Chen
Journal:  Lipids Health Dis       Date:  2018-05-17       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.